Guardant HealthMEX:GH 13 PS Ratio is 16.71 as of Jul. 06, 2026, which is 19% above its 10-year median of 14.03. GuruFocus rates MEX:GH with a GF Score™ of 13/100 and a GF Value™ of MXN1,341.84 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Guardant Health ranks worse than 93.07% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Guardant Health's share price is MXN2590.00.
Guardant Health's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was MXN154.98. Hence, Guardant Health's PS Ratio for today is 16.71.
Warning Sign:
Guardant Health Inc stock PS Ratio (=19.83) is close to 3-year high of 19.83.
The historical rank and industry rank for Guardant Health's PS Ratio or its related term are showing as below:
MEX:GH'
s PS Ratio Range Over the Past 10 Years
Min: 3.11 Med: 14.03 Max: 88.19
Current: 19.83
During the past 10 years, Guardant Health's highest PS Ratio was 88.19. The lowest was 3.11. And the median was 14.03.
MEX:GH's PS Ratio is ranked worse than 93.07% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.855
vs MEX:GH: 19.83
During the past 12 months, the average Revenue per Share Growth Rate of Guardant Health was 35.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 21.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 20.40% per year.
During the past 10 years, Guardant Health's highest 3-Year average Revenue per Share Growth Rate was 87.80% per year. The lowest was 7.40% per year. And the median was 21.20% per year.
Back to Basics: PS Ratio
Guardant Health (MEX:GH) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Guardant Health PS Ratio Related Terms
Guardant Health PS Ratio Historical Data
* Premium members only.
The historical data trend for Guardant Health's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Guardant Health's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's PS Ratio distribution charts can be found below:
* The bar in red indicates where Guardant Health's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Guardant Health's Share Price of today is MXN2590.00. Guardant Health's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN154.98.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Guardant Health (MEX:GH) has a PS Ratio of 16.71 as of Jul. 06, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Guardant Health and its competitors. This is 19% above median its historical median of 14.03. Over the past decade, Guardant Health's PS Ratio has ranged from 3.11 to 88.19. According to the industry distribution chart, Guardant Health ranks #188 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 93.1%.
Is Guardant Health's PS Ratio too high?
Guardant Health's current PS Ratio of 16.71 is 19% above median its 10-year median of 14.03. Over the past 10 years, this metric has ranged from a low of 3.11 to a high of 88.19. The Medical Diagnostics & Research industry median PS Ratio is 2.86. Guardant Health's value of 16.71 is 485.3% above this industry median. Based on the distribution chart, Guardant Health ranks #188 out of 202 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Guardant Health has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guardant Health's PS Ratio compare to LH and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Guardant Health ranks #188 out of 202 companies for PS Ratio. This places Guardant Health in the lower half of its industry. The industry median PS Ratio is 2.86. Guardant Health's value of 16.71 is 485.3% above this benchmark. Historically, Guardant Health's own PS Ratio has ranged from 3.11 to 88.19 over the past decade. While the company's 10-year median is 14.03 vs. the industry median of 2.86, Guardant Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.86, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guardant Health's current PS Ratio of 16.71 is 485.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Guardant Health and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guardant Health's current PS Ratio is 16.71, which is 19% above median its own 10-year median of 14.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardant Health stock overvalued right now?
Based on GuruFocus' analysis, Guardant Health (MEX:GH) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN1,341.84, compared to a current price of MXN2,590.00 — trading 93% above its estimated fair value. The current PS Ratio is 16.71, which is 19% above median its 10-year median of 14.03 and 485.3% above the Medical Diagnostics & Research industry median of 2.86. Guardant Health's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Guardant Health (MEX:GH), the current PS Ratio is 16.71 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guardant Health (MEX:GH) Overvalued in 2026?
Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued.
The current stock price of MXN2,590.00 is trading 93% above its estimated GF Value™ of MXN1,341.84.
GuruFocus considers Guardant Health to be Significantly Overvalued.
Key valuation signals for MEX:GH:
PS Ratio: 16.71 (19% above median its 10-year median of 14.03)
GF Value™: MXN1,341.84 vs. price of MXN2,590.00 (93% above fair value)
Industry Position: 485.3% above the Medical Diagnostics & Research median (#188 of 202)
No single metric tells the full story. See the MEX:GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
13GF Score
Get the complete analysis for MEX:GH
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GH has been successfully added to your 
